No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights
Home Compliance

FDA Regulation of Medical Device Advertising and Promotion

by Areta L. Kupchyk
November 17, 2018
in Compliance
FDA Regulation of Medical Device Advertising and Promotion

Updated 2018

There are tens of thousands of medical devices being advertised and promoted in the U.S. The Food and Drug Administration (FDA) has statutory authority to regulate the advertising and promotion of “restricted” medical devices as well as any medical devices that are not authorized by FDA for sale or distribution for their intended use. A “restricted device” is a device that can only be sold, distributed or used upon the order of an authorized healthcare provider, generally referred to as prescription (Rx) devices.

Devices that are not authorized for marketing include experimental (or investigational) devices as well as approved or cleared devices that are marketed for uses not on their approved or cleared labels (“off-label uses”). In both cases, the unauthorized intended use of the device would render the device “misbranded.”

A medical device is misbranded if its advertising is “false or misleading” in any way. The false and misleading standard also applies to a product’s labeling and “other descriptive printed matter.” A device is also misbranded if its label does not contain certain required information, such as: (1) the generic name of the product in type at least half the size of the trade name; (2) a brief statement of the intended uses and warnings, precautions, side effects and contraindications; and (3) when needed, a description of the device’s components. (21 U.S.C. § 352(q)).

By way of background and to appreciate the full scope of FDA’s authority over products that are considered to be medical devices, it is interesting (if not mind-boggling) to review the broad statutory definition of a medical device. A medical device is defined as:

“…an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is—

(1) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them,

(2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or

(3) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. (21 U.S.C. 301(h)(emphasis added).”

From this definition, it’s clear that “intended use” is the key in determining regulatory status and compliance. FDA determines the intended use of a medical device by looking at a wide body of evidence, such as: “labeling claims, advertising matter, or oral or written statements” or circumstances that show the medical device is “with the knowledge of [the manufacturer] offered and used for a purpose for which it is neither labeled nor advertised.” (21 C.F.R. § 801.4) (emphasis added). In determining whether labeling or advertising is misleading, the FDA considers everything: statements or any other representations, explicitly made or implied by “word, design, device or any combination” of these, as well as the “extent to which the labeling or advertising fails to reveal facts that are material, such as information about the risks from using the device either on or off-label. (21 U.S.C. 301(n)).

Device advertising is different from drug advertising. The most obvious difference is the complete absence of any regulations to guide medical device companies in developing their advertising. By contrast, the FDA has an extensive and detailed regulation (21 C.F.R. Part 202) that sets out the requirements as well as the prohibitions for drug advertising.

For example, FDA regulations require drug advertising to include fair balance between the benefits and risks of the product, as well as specific language and size of print. The drug regulations explicitly prohibit, among other things, unsubstantiated efficacy, comparability and superiority claims. Although the same detailed regulations have not been imposed by FDA, the agency applies many of these same restrictions on medical devices.

Although the FDA is prohibited from the regulation of “commercial free speech” under the First Amendment, and may not impose preapproval requirements for either drugs or devices, the FDA has carved out an exception for drugs when the drug is approved through an accelerated pathway or when the FDA finds that the drug pose such risks that preapproval of advertising is needed to protect the public health. By contrast, the FDA has not imposed a similar preapproval review for medical devices.

The FDA enforces the advertising and promotion of medical devices in a variety of ways. The first and obvious way is by reviewing labeling and other publicly disseminated materials. The FDA can find advertising and promotional materials from any source or by any means, such as reading product web pages and surfing the Internet to learn how a device is being used by consumers. In addition, FDA compliance reviewers attend trade shows and scientific/medical conferences, read periodicals and inspect company facilities.

Of great concern to most companies is having a level playing field when competing in the market. To this end, many companies file trade complaints with the FDA in which they detail violations, provide copies of the violative materials and analyze the legal basis for FDA to take an enforcement action. Such letters attempt to make it as easy as possible for FDA to take action. The FDA states that it reviews all complaints, but whether the FDA will take action is never revealed. Nor will the FDA inform the complainant when it does take action. To a lesser extent and without as much analysis, the FDA receives complaints from healthcare providers, and sometimes consumers.

To leverage its limited resources, the FDA focuses first on higher risk medical devices in addition to unapproved medical devices that have the potential to lead to injury. For example, if the agency must make a choice, the FDA would be more likely to focus on cardiac implants instead of exercise equipment.

From the small amount of information and guidance the FDA has offered to date, we know how the FDA would view certain statements and representations. For example, companies are permitted to state that a medical device is approved if, in fact, the device has been “approved” under a premarket application (PMA), which is required for high risk devices. However, the FDA does not permit the use of the phrase “FDA approved” when referring to a device brought to market via the 510(k) notification process.

A 510(k) device is generally of low to moderate risk. Despite the premarket submission requirements, a 510(k) medical device is not “FDA-approved.” Rather, such a device is “cleared” by the agency.

With respect to PMA devices, a manufacturer must demonstrate the safety and efficacy of its medical device typically with clinical studies. A manufacturer of a 510(k) medical device only needs to show that the device is substantially equivalent to a legally marketed 510(k) device, referred to as the predicate device. If substantial equivalence is shown, the device is considered as safe and effective as the predicate without presentation of independent evidence of safety and effectiveness. To say a 510(k) device is approved would be false and misleading and, thus, prohibited.

The world of medical device regulation is complex and often maddening. But a surefire way to show your familiarity with medical devices is to be sure to refer to a 510(k) device as cleared for its intended use and a PMA device as approved.


Previous Post

Keeping Your Whistleblower Hotline Alive

Next Post

Don’t Mistake Execution for Strategy, or You’ll Jeopardize Both

Areta L. Kupchyk

Areta L. Kupchyk

Areta Kupchyk is a partner with Nixon Peabody LLP who provides counsel to clients on the U.S. Food and Drug Administration (FDA) regulation of drug, medical device, biotechnology, and biologic products. Formerly an Associate Chief Counsel for Drugs and Biologics and Assistant General Counsel for Litigation at the FDA, Ms. Kupchyk possesses a nuanced understanding of FDA regulatory procedure that allows her to insightfully navigate clients through all phases of product development, review, and approval, including obtaining approvals with market protections such as three-year market exclusivity for new indications requiring clinical studies, five-year market exclusivity for new chemical entities, and seven-year market exclusivity for orphan drugs.  

Related Posts

parliament

Coming Soon to the UK: Sweeping Corporate Criminal Liability Reforms?

by Peters and Peters
March 28, 2023

UK legislators have proposed major amendments to the Economic Crime and Corporate Transparency Bill currently passing through Parliament. If adopted,...

wind turbines

What Companies Around the Globe Need to Know About EU Sustainability Reporting

by John Peiserich
March 28, 2023

By the beginning of next year, large companies in the EU or that do a substantive amount of business in...

amsterdam

At a Gathering of Compliance Practitioners, No Shortage of Food for Thought

by Mary Shirley
March 28, 2023

Last week, about 300 ethics and compliance professionals descended upon Amsterdam’s Hotel Okura to participate in SCCE’s European Compliance &...

documents

Meeting Accounting Standards in an Uncertain Economy

by Tom Zauli
March 28, 2023

After a Covid-related grace period, new contract accounting standards — ASC 606 — are in effect for both public and...

Next Post
man with hands folded behind chess set

Don’t Mistake Execution for Strategy, or You’ll Jeopardize Both

Compliance Job Interview Q&A

Jump to a Topic

AML Anti-Bribery Anti-Corruption Artificial Intelligence (AI) Automation Banking Board of Directors Board Risk Oversight Business Continuity Planning California Consumer Privacy Act (CCPA) Code of Conduct Communications Management Corporate Culture COVID-19 Cryptocurrency Culture of Ethics Cybercrime Cyber Risk Data Analytics Data Breach Data Governance DOJ Download Due Diligence Enterprise Risk Management (ERM) ESG FCPA Enforcement Actions Financial Crime Financial Crimes Enforcement Network (FinCEN) GDPR HIPAA Know Your Customer (KYC) Machine Learning Monitoring RegTech Reputation Risk Risk Assessment SEC Social Media Risk Supply Chain Technology Third Party Risk Management Tone at the Top Training Whistleblowing
No Result
View All Result

Privacy Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2022 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe

© 2022 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT